Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
LY2109761
Cat No.
CEI-0313
Description
As a novel inhibitor, LY2109761 can TGF-beta receptor type I and TGF-beta receptor II with Ki of 38 nM and 300 nM, respectively.
CAS No.
700874-71-1
Molecular Weight
441.52
Purity
>99%
Storage
2 years at -20 centigrade
Targets
TGF-beta receptor I, TGF-beta receptor II
Molecular Formula
C26H27N5O2
Chemical Name
7-(2-morpholinoethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline
Solubility
DSMO
In vitro
LY2109761 treatment induces a dose-dependent low-anchorage growth inhibition of L3.6pl/GLT cells, leading to ~33% or 73% inhibition at 2 uM and 20 uM. And LY2109761 treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression.
In vivo
Administration of LY2109761 (50 mg/kg) alone or in combination with gemcitabine (25 mg/kg) significantly reduces the tumor volume by ~70% and ~90%. In consistent with the in vitro effect, administration of LY2109761 alone or in combination with radiation, markedly inhibits tumor growth in the orthotopical CSLC glioblastoma model by 43.4% and 76.3%, respectively.
Download
Download Datasheet